China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Adaptive Biotechnologies (NASDAQ:ADPT) Chief Financial Officer Kyle Piskel sold 238 shares of common stock on November 17, 2025, at a price of $14.05, for a total transaction value of $3343. The stock, currently trading at $13.75, has shown remarkable performance with a 207% return over the past year despite recent volatility. According to InvestingPro data, ADPT has a market capitalization of approximately $2.1 billion.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). The filing indicates that the sale was mandated by Adaptive Biotechnologies’ equity incentive plans and does not represent a discretionary trade by Piskel. Following the transaction, Piskel directly owns 269,343 shares of Adaptive Biotechnologies.InvestingPro analysis indicates ADPT is currently overvalued based on its Fair Value assessment. Analysts maintain a "Strong Buy" consensus with price targets ranging from $15 to $22. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for ADPT and 1,400+ other US equities.
In other recent news, Adaptive Biotechnologies reported impressive financial results for the third quarter of 2025. The company exceeded market expectations with an earnings per share (EPS) of $0.06, significantly higher than the forecasted -$0.17. Revenue also surpassed projections, reaching $94 million compared to the anticipated $60.48 million. This performance marked a revenue surprise of 55.37%. These results highlight a strong quarter for Adaptive Biotechnologies, showcasing their ability to outperform analyst predictions. The company’s earnings announcement has captured the attention of investors, reflecting its positive financial health. Analysts from various firms are likely to consider these results in their future assessments. This development is a key point of interest for those tracking Adaptive Biotechnologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.